Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Passes Above 200 Day Moving Average – Should You Sell?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $47.89 and traded as high as $55.17. Global X Genomics & Biotechnology ETF shares last traded at $54.83, with a volume of 25,295 shares trading hands.

Global X Genomics & Biotechnology ETF Trading Down 0.5%

The business has a 50-day moving average of $51.30 and a two-hundred day moving average of $47.89. The firm has a market cap of $83.89 million, a P/E ratio of -23.43 and a beta of 1.16.

Global X Genomics & Biotechnology ETF Announces Dividend

The business also recently declared a dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 29th were paid a $0.0579 dividend. The ex-dividend date of this dividend was Monday, June 29th. Global X Genomics & Biotechnology ETF’s payout ratio is -27.35%.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Institutional investors and hedge funds have recently made changes to their positions in the stock. IFP Advisors Inc grew its stake in shares of Global X Genomics & Biotechnology ETF by 20.8% in the 3rd quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock valued at $110,000 after buying an additional 489 shares during the period. Wealth Management Partners LLC bought a new position in Global X Genomics & Biotechnology ETF in the first quarter worth approximately $244,000. Creative Financial Designs Inc. ADV grew its stake in Global X Genomics & Biotechnology ETF by 4.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock valued at $551,000 after acquiring an additional 481 shares during the period. U.S. Capital Wealth Advisors LLC acquired a new stake in Global X Genomics & Biotechnology ETF in the fourth quarter valued at approximately $575,000. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Global X Genomics & Biotechnology ETF by 30.9% during the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock valued at $164,000 after acquiring an additional 4,615 shares in the last quarter. Institutional investors own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.